Mankind Pharma Limited
Mainboard₹14,040 / 13 Shares
Mankind Pharma Limited IPO Details
The Mankind Pharma Limited IPO price band is set between ₹1026-1080 per equity share, with a face value of ₹1 per share. The issue is managed by KFin Technologies Limited, and the equity shares are proposed to be listed on the Mainboard.
The IPO date for subscription opens on 25 Apr, 2023 and closes on 27 Apr, 2023. Investors can check the allotment status on 3 May, 2023, while the listing date is tentatively scheduled for 9 May, 2023.
The total issue size is 40,058,844 shares, aggregating up to ₹4,326.36 Cr Offer for Sale. Stay tuned for the latest Mankind Pharma Limited IPO review and GMP updates.
Mankind Pharma Limited IPO Review, Rating & Analysis
Mankind Pharma Limited IPO Review
NO REVIEWMankind Pharma Limited IPO Rating
Mankind Pharma Limited IPO Highlights
IPO Date
Apr 25, 2023 - Apr 27, 2023
Listing Date
9 May, 2023
Face Value
₹1 Per Equity Share
Price Band
₹1026-1080 per equity share
Lot Size
-
Fresh Issue
Shares
Offer for Sale
-
Listing At
BSE, NSE
Mankind Pharma Limited IPO Lot Size
The minimum market lot for Mankind Pharma Limited IPO is 13 shares with an application amount of ₹14,040. Retail investors can apply for up to 14 lots. The table below details the minimum and maximum investment limits for Retail and HNI investors.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 13 | ₹14,040 |
| Retail (Max) | 14 | 182 | ₹1,96,560 |
| S-HNI (Min) | 15 | 195 | ₹2,10,600 |
| S-HNI (Max) | 71 | 923 | ₹9,96,840 |
| B-HNI (Min) | 72 | 936 | ₹10,10,880 |
Mankind Pharma Limited IPO Timeline
Issue Price
₹1026-1080 per equity shareFace Value
₹1 Per Equity ShareListing at Group
BSE, NSERegistrar
KFin Technologies LimitedLead Manager
Kotak Mahindra Capital CompanyAxis Capital LimitedIIFL Securities LtdJefferies India Private LimitedJ.P. Morgan India Private LimitedIssue Size
40,058,844 shares(aggregating up to ₹4,326.36 Cr Offer for Sale)Mankind Pharma Limited IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31 Dec 22 | 9273.75 | 6777.82 | 1015.98 | - | - | - |
| 31 Mar 22 | 9147.74 | 7977.58 | 1452.96 | - | - | - |
| 31 Mar 21 | 6372.63 | 6385.38 | 1293.03 | - | - | - |
| 31 Mar 20 | 5073.29 | 5975.65 | 1056.15 | - | - | - |
All values are in ₹ Cr.
Promoters & Share Holding
Promoter(s) Name
- Ramesh Juneja
- Rajeev Juneja
- Sheetal Arora
- Ramesh Juneja Family Trust
- Rajeev Juneja Family Trust
- Prem Sheetal Family Trust
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| 79.00% | 76.50% |
About Company
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
The company has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among these.
The company has its presence in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market (IPM). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
Mankind Pharma Limited IPO Subscription Details
| As on | QIB | NII bNII sNII | Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 8,011,769 | 6,008,827 4,005,885 2,002,942 | 14,020,596 | 28,041,192 |
Day 1 -25-04-23 05:00 PM | 0.08 x | 0.33 0.37 x 0.25 x | 0.10 x | 0.14 x |
Day 2 -26-04-23 05:00 PM | 1.86 x | 1.02 1.21 x 0.64 x | 0.25 x | 0.87 x |
Day 3 -27-04-23 05:00 PM | 49.16 x | 3.80 4.99 x 1.41 x | 0.92 x | 15.32 x |
Frequently Asked Questions about Mankind Pharma Limited IPO
When will Mankind Pharma Limited IPO open for subscription?
The Mankind Pharma Limited IPO opens on 25 Apr, 2023 and closes on 27 Apr, 2023.
What is the investors portion for Mankind Pharma Limited IPO?
The investors' portion for QIB is 49.16 x, NII is 4.99 x, and Retail is 0.92 x.
How to apply for Mankind Pharma Limited IPO?
You can apply for Mankind Pharma Limited IPO via ASBA online through your bank account. You can also apply via UPI through stock brokers like Zerodha, Upstox, or Paytm Money.
What is the issue size of Mankind Pharma Limited IPO?
The issue size of Mankind Pharma Limited IPO is approx ₹40,058,844 shares(aggregating up to ₹4,326.36 Cr Offer for Sale) crores.
What is the price band of Mankind Pharma Limited IPO?
The price band for Mankind Pharma Limited IPO is ₹1026 to ₹1080 per equity share.
What is the lot size of Mankind Pharma Limited IPO?
The minimum bid (lot size) for Mankind Pharma Limited IPO is N/A shares with an investment of approx ₹14,040 .
What is the allotment date of Mankind Pharma Limited IPO?
The allotment date for Mankind Pharma Limited IPO is 3 May, 2023.
What is the listing date of Mankind Pharma Limited IPO?
The listing date for Mankind Pharma Limited IPO is expected to be 9 May, 2023.
What is the GMP of Mankind Pharma Limited IPO?
The latest Grey Market Premium (GMP) for Mankind Pharma Limited IPO is being updated regularly on IPOROCK.
Parth D.
Founder & Lead Analyst
Parth D. is a software engineer and financial analyst who brings a quantitative edge to IPO tracking. With deep expertise in algorithmic trading and financial tool development, he builds the technology that powers IPORock's real-time data engines. He has been tracking the Indian market since 2018.